Accordingly, combination therapies that incorporate DOX with agents targeting GRIN2D or related pathways are being explored as strategies to improve therapeutic outcomes in patients with HCC (Duan and Liu, 2018). Here, GRIN2D is linked to hepatocellular carcinoma.